𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Human papillomavirus seropositivity and risks of head and neck cancer

✍ Scribed by Elaine M. Smith; Justine M. Ritchie; Michael Pawlita; Linda M. Rubenstein; Thomas H. Haugen; Lubomir P. Turek; Eva Hamsikova

Publisher
John Wiley and Sons
Year
2006
Tongue
French
Weight
115 KB
Volume
120
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We examined antibody response to VLP HPV‐16, HPV‐16 E6 and E7 antibodies as potential seromarkers of HPV‐related head and neck cancer (HNC). The study included 204 HNC cases and 326 controls evaluated for HPV presence in sera using ELISAs for anti‐HPV VLP antibodies and HPV‐16 E6 and/or E7 antibodies, and in tumor tissue using PCR and DNA sequencing. Anti‐HPV‐16 VLP was detected in 33.8% of cases and 22.4% of controls, anti‐E6 in 20.6% of cases and 0.9% of controls and anti‐E7 in 18.6% of cases and 0.6% of controls. HPV‐16 DNA was detected in 26.1% of tumors. The adjusted risk of HNC was elevated among those seropositive for HPV‐16 VLP (odds ratio (OR) = 1.7, 1.1–2.5), E6 (OR = 32.8, 9.7–110.8) or E7 (OR = 37.5, 8.7–161.2). Compared to HPV DNA‐negative/seronegative cases, tumor HPV‐16 cases had increased risk of detection with anti‐VLP antibodies (OR = 6.8, 3.1–14.9). The odds were more pronounced among cases seropositive for E6 (OR = 69.0, 19.3–247) or E7 (OR = 50.1, 14.7–171). Antibodies against E6 or E7 were associated with risk of cancer in the oral cavity (OR = 5.1, 1.2–22.4) and oropharynx (OR = 72.8, 16.0–330), and with disease characteristics: stage, grade and nodal status. Anti‐E6 and/or E7 antibodies were found in 74% of tumor HPV‐16 positive cases but in only 5% of tumor HPV‐negative cases (K =0.7, 0.6–0.8) suggesting good correlation between the serologic marker and HPV tumor status. Antibodies to HPV‐16 E6 and/or E7 represent a more specific biomarker than anti‐HPV‐16 VLP of an HPV‐related HNC. Because of the survival advantage of HPV‐related HNC, HPV‐16 E6/E7 detection may be useful in therapy targeted for HPV‐related tumors. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Human Papillomavirus and head and neck c
Human Papillomavirus and head and neck cancer: Epidemiology and molecular biology
✍ Rosemary G. McKaig; Ralph S. Baric; Andrew F. Olshan 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

Background. Human papillomaviruses (HPV) are known to cause cancers of the cervix and other anogenital tract sites. Molecular biology has provided some evidence as to the specific mechanisms involved in the HPV-related carcinogenesis. Epidemiologic and molecular biology studies have also suggested t

Human papillomavirus-active head and nec
Human papillomavirus-active head and neck cancer and ethnic health disparities
✍ Paul M. Weinberger; Mark A. Merkley; Sunny S. Khichi; Jeffrey R. Lee; Amanda Psy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB

## Abstract ## Objectives/Hypothesis: Mortality for black males with head and neck squamous cell carcinoma (HNSCC) is twice that of white males or females. Human papillomavirus (HPV)‐active HNSCC, defined by the concurrent presence of high‐risk type HPV DNA and host cell p16^INK4a^ expression, is

Role of human papillomavirus in the etio
Role of human papillomavirus in the etiology of head and neck cancer
✍ Nham Tran; Barbara R. Rose; Christopher J. O'Brien 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract Head and neck cancer is the world's sixth most common cancer, but despite advances in treatment, there has been no significant decline in the mortality rate. In recent years, there has been mounting epidemiologic and experimental evidence of a role for human papillomavirus (HPV) as the

Human papillomavirus 16 and head and nec
Human papillomavirus 16 and head and neck squamous cell carcinoma
✍ C. Sloane Furniss; Michael D. McClean; Judith F. Smith; Janine Bryan; Heather H. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 101 KB 👁 2 views

## Abstract Evidence suggests that human papillomavirus (HPV)16 seropositivity reflects past HPV16 exposure and is associated with risk for head and neck squamous cell carcinoma (HNSCC). Our objectives were to test the hypothesis that HPV16 seropositivity is associated with risk for HNSCC, to corre

Genetic polymorphisms in head and neck c
Genetic polymorphisms in head and neck cancer risk
✍ Jeffrey E. McWilliams; Adam J. Evans; Tomasz M. Beer; Peter E. Andersen; James I 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views